|Dr. Andrew R. Allen||Co-Founder, Pres, CEO & Director||730.85k||N/A||1967|
|Mr. Jean-Marc Bellemin M.B.A.||Exec. VP of Fin. & CFO||540.66k||N/A||1972|
|Dr. Roman Yelensky||Exec. VP & CTO||472.78k||N/A||1979|
|Dr. Karin Jooss||Exec. VP of Research & Chief Scientific Officer||N/A||N/A||1965|
|Mr. Mike Forcht||Sr. VP of HR||N/A||N/A||N/A|
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Gritstone Oncology, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.